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Volume 49, Number 5S Plenary Sessions 5Swas equivalent in groups. All patients were treated with atorvastatin (10-
80mg gradual titration) to reach the target. Biochemical parameters and
GSM score were assessed at baseline and after 12 months. Independent
samples t-test and Pearson correlation were used for statistical analysis
(p0.05).
Results: There were no significant differences between groups at
baseline. Group A showed a more pronounced improvement in lipid profile
compared with group B (p0.05). Moreover atorvastatin treatment signif-
icantly suppressed of hsCRP, OPN and OPG serum levels across LDL levels
downregulation (p0.05). ). Remarkable increment of carotid plaque echo-
genicity was noted in both groups, but that was considerably higher in group
A than group B (table 1).Notably GSM score augmentation was inversely
associated with OPN (p0.031) and OPG (p0.002) changes in the whole
study group.
Conclusions: Intensive lipid-lowering therapy rather than moderate
lipid-lowering therapy is more effective in increasing echogenicity of carotid
plaques. This effect seems to be mediated by OPN and OPG suppression.
Table 1. Changes of lipid parameters, osteopontin,
osteoprotegerin, hsCRP and GSM in both groups
Group A Group B
pBaseline Change Baseline Change
T.Cholesterol
(mg/dl)
200.644.1 68.517.2* 20950.6 45.114.3* 0.048
HDL-C (mg/
dl)
36.610 4.61.1* 34.213.6 1.30.5 0.017
LDL-C (mg/dl) 153.836.5 7422.9* 146.143.3 44.910.8* 0.018
Triglycerides
(mg/dl)
151.350.2 3714.4* 168.772.4 36.79.2* 0.984
Osteopontin
(ng/ml)
74.6328.64 45.924.6* 71.8931.58 22.411.5* 0.002
Osteoprotegerin
(pmol/L)
7.041.58 3.82.3* 7.562.37 2.841.3* 0.038
hsCRP (mg/L) 5.372.35 2.881.1* 5.53 2.10.55* 0.067
GSM 63.717.6 28.035.92* 63.112.6 20.814.33* 0.030
p values of changes of variables between groups (A vs B).
*p0.05 values of changes of variables within groups.
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SS12.
Unexpected Major Role for Venous Stenting in Reflux Disease: Symp-
tom Relief With Partial Correction of Pathology
Seshadri Raju1,2, Rikki Darcey2, Peter Neglen2. 1University of Mississippi
Medical Center, Jackson, MS; 2River Oaks Hospital, Flowood, MS
Background: Pathology of Postthrombotic venous disease (PTS) has
been known to be a combination of obstruction and reflux. Recent use of
IVUS has found that obstructive non-thrombotic iliac vein lesions (NIVL)
are found in over 90% of symptomatic ‘primary’ cases with reflux as well.
Correction of the obstructive component alone in both types of chronic
venous insufficiency (CVI) yielded unexpected substantial symptom relief
minimizing the need for correction of associated reflux with complex open
surgery.
Patients and Methods: From 1997 to 2008 (11yrs) iliac vein stent
procedures were performed in 1487 limbs to relieve obstruction. 513 had
associated deep reflux (with superficial reflux in 366, 71%). Superficial reflux
alone was present in 345 and excluded. Clinical (CEAP) classification was
C2 (pain) in 4%; C3 in 44%; C4 in 21%; C5 in 6%; and C6 in 25%. Etiology
was ‘primary’ in 213 (42%) and postthrombotic in 300 (58%) limbs. Reflux
segment score was 3, (0-8) (median, range). Severe reflux (reflux segment
score3 and/or axial reflux) was present in 296 (58%) which also included
271 limbs with ‘axial reflux.’ Median (range) percentage drop & VFT
(ambulatory venous pressure) were 62 % (10-90) mm Hg & 16 sec. (1-23)
respectively; median VFI 90 (APG) was 2.8 sec (0.5-16.6).
Results: Cumulative secondary stent patency (6 Yrs) was 100 % and 87
% respectively for NIVL and PTS limbs. Complete relief of pain occurred in
83 % and significant improvement ( 3 VAS) in 89% post-stent. Complete
relief of swelling occurred in 46% and significant improvement ( 1 grade)
in 71% post-stent. Complete healing/freedom from recurrence (C 4,5,6)
was 63% at 5 years. QOL (CIVIQ) improved significantly. Clinical outcomes
were similar (p NS) between NIVL and PTS limbs and between severe orlesser reflux subsets. Reflux parameters did not get worse post stent: per-
centage drop- 63% mmHg (10-90) and VFT 16 sec. (1-23) were un-
changed; VFI90 2.1 sec. (0.5-13.2) was improved (p0.002).
Conclusions: Combined obstruction/reflux is often present in CVI of
post-thrombotic or primary aetiologies. Substantial symptom relief is ob-
tained by percutaneous stenting alone ie. CVI responds to partial correction
of combined pathology with stent and the residual reflux is well tolerated.
These findings provide the basis for a new paradigm in the treatment of CVI.
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High Brachial Artery Bifurcation Is Associated With Failure Of Upper
Limb Autologous Arteriovenous Fistulae
Domenico Valenti, HirenMistry, Cornelia Junghans, NiamhHaughey, Ben
Freedman, Mark Tyrrell. King’s College Hospital, London, United King-
dom
Objective: Although European Best Practice Guidelines on vascular
access recommend universal pre-operative duplex scan in patients receiving
brachio-cephalic (BC) arteriovenous fistulae (AVF), this is not widespread
practice. Furthermore, cadaveric and angiographic studies suggest that
variation in upper limb arterial anatomy is common. Our aim was to
investigate the prevalence of high brachial artery bifurcation and its impact
on BC AVF patency.
Methods: A prospective analysis of consecutive autologous BC AVF
procedures over an 18 month period (January 2007-June 2008). Patients
with high bifurcations identified at duplex scan were compared with a
randomly selected age and sex matched population of those with normal
bifurcations. Patients were followed up at 1, 6 and 12weeks post operatively.
The study endpoint was AVF failure.
Results: 258 procedures were performed on 239 patients (male: female
ratio 150:89, median age 64, range 29-88). 29 (12%, of whom 57% were
male) had high brachial bifurcations. The bifurcation was axillary in 6
patients and at the proximal, middle and distal third humerus level in 9, 7
and 7 patients respectively. At 12 months, the actuarial risk of AVF failure
was greater in those with high than those with normal bifurcations (45%
(95% CI 26-69%) vs. 23% (95% CI 14-37%). Neither gender nor cause of
renal failure predicted either aberrant upper limb arterial anatomy or AVF
failure.
Conclusions: These data show that aberrant brachial artery anatomy is
both common (12%) and a powerful independent predictor of AVF failure.
These data support the universal use of pre-AVF duplex scanning.
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Brachial Vein Transposition Arteriovenous Fistulas for Hemodialysis
Access
William C Jennings, Matthew J Sideman, Kevin E Taubman, Thomas A
Broughan. University of Oklahoma College of Medicine, Tulsa, Tulsa, OK
Background: The National Kidney Foundation Dialysis Outcomes
Quality Initiative and the National Vascular Access Improvement Initiative
“Fistula First” recommend arteriovenous fistulas (AVF) as the preferred
vascular access for hemodialysis. AVFs have lower morbidity and mortality
rates in addition to lower yearly Medicare cost profiles, as opposed to grafts
or catheters. Complex medical illnesses and previous failed access operations
leave some individuals with a difficult access extremity, confronting surgeons
with obliterated cephalic and basilic veins. Brachial vein transposition AVFs
(BVT-AVF) have been reported with mixed results in these patients. We
review our experience and techniques with BVT-AVFs.
Methods: We analyzed the records of consecutive patients in our
vascular access database who had BVT-AVFs constructed from September
2006 to December 2008. Most BVT-AVFs were created in staged proce-
dures. The second stage transposition operations were generally completed
4 to 6 weeks after the first stage AVF operation. A single stage BVT-AVFwas
utilized when the brachial vein diameter was  6 mm. All patients were
evaluated with pre and post-operative ultrasound examinations by the
operating surgeon.
Results: 52 BVT-AVF procedures were identified. Of these, 35(67.3%)
were women, 25(48.1%) were diabetic, and 26 (50.0%) had previous access
surgery. 46 operations were completed in two stages and 6 as a single
procedure. Follow-up was 1-25 months (mean  6 mos). Primary patency,
primary assisted patency, and cumulative (secondary) patency were 33.5%,
79.8%, and 91.7% at 12 months and 25.1%, 79.8%, and 91.7% at 24 months,
respectively. No prosthetic grafts were used in any patient.
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access when the basilic vein is absent in patients with difficult access extrem-
ities. Most patients required one or more interventional procedures. Cumu-
lative (secondary) patency was 91.7% at 24 months.
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Fenestrated and Branched Endograft Repair of Juxta- and Para-renal
Aneurysms after Previous Open Aortic Reconstruction
Adam W. Beck1,2, Wendy T. G. Bos2, Georgios Vourliotakis23, Clark J.
Zeebregts2, Ignace F. J. Tielliu2, Eric L. G. Verhoeven2. 1Dartmouth-
HitchcockMedical Center,West Lebanon, NH; 2UniversityMedical Center
of Groningen, Groningen, TheNetherlands, Netherlands; 3GeneralMilitary
Hospital of Athens, Athens, Greece, Greece
Objective: Para-anastomotic aneurysms and progressive aneurysmal
degeneration after previous open aortic reconstruction pose a difficult
scenario. Due to proximity to the visceral arteries, endovascular exclusion is
typically not an option. Fenestrated and branched endografts provide a less
invasive means of repair. We sought to evaluate our experience with fenes-
trated endografts in the management of juxta- and para-renal aneurysms
after previous open reconstruction.
Methods: This analysis was based on a prospective database gathered
from March 2004 to November 2008. Patients underwent repair under the
direction of a single surgeon using customized Cook endografts manufac-
tured based on preoperative imaging.
Results: 18 patients were treated over the study interval. All patients
had a previous open aortic reconstruction. Mean time since the operation
was 8.5 years (range 1 to 15 years). Mean patient age was 72 years (range 57
to 80 years). All patients were considered high risk for open surgery due to
co-morbidities and/or the redo nature of their surgery. The mean number
of fenestrations per patient was 3, including proximal graft scallops. All but
one (94%) was completed by totally endovascular means. One operation
required a planned celiotomy for retrograde access to a left renal artery. Of
56 target vessels, all were successfully re-vascularized with a combination of:
fenestrations with bare metal (12) or covered stents (25), as well as graft
branches (1), or graft scallops (18). Mean operative time was 215 minutes
(range 135-420 minutes) and mean blood loss was 560cc (range 100 to
1500cc). 30-day and 1-year mortality was 0 and 11%, respectively. Peri-
operative complications occurred in 2 patients. One developed a congestive
heart failure exacerbation and myocardial infarction and one a groin wound
infection. Mean follow-up time was 23 months and cumulative primary
patency was 95% (53/56 vessels), with no follow-up interventions required.
Conclusions: Endovascular treatment of juxta- and para-renal aneu-
rysms after prior aortic reconstruction is a viable alternative to open repair
with high success and low re-intervention rates. These devices will broaden
the available treatment modalities for these conditions, and will likely
decrease the complication rate of treatment in these high-risk patients.
Author Disclosures: A.W. Beck, None; W.T.G. Bos, None; G. Vourlio-
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30 Day Mortality From Reintervention or Readmission Following
Endovascular and Open Repair of Abdominal Aortic Aneurysms in the
United States Medicare Population
Marc L Schermerhorn1, Kristina A Giles1, A James O’Malley2, Philip
Cotterill2, Frank B Pomposelli1, Bruce E Landon2. 1Beth Israel Deaconess
Medical Center, Boston, MA; 2Harvard Medical School, Boston, MA
Objective: Late survival is similar after EVAR and open AAA repair
(OAR) despite a perioperative benefit with EVAR. AAA-related reinterven-
tions are more common after EVAR while laparotomy related reinterven-
tions are more common after OAR. The impact of reinterventions on
survival, however, is unknown.
Methods: Using propensity score matched Medicare beneficiaries
(n45,652) undergoing EVAR and OAR from 2001-2004, AAA and
laparotomy-related reinterventions through 2006 were identified. A hierar-
chical severity scheme was utilized within each hospitalization to avoid
counting multiple adjunctive procedures. Hospitalizations for ruptured
AAA without repair and for bowel obstruction or ventral hernia without
abdominal surgery as well as amputations were also recorded. 30 day
mortality was calculated for each reintervention or readmission.Results: Overall reinterventions or readmissions were similar between
repair methods but slightly more common after EVAR (Table). EVAR patients
had more ruptures (mortality 27%). EVAR patients also had more AAA-related
reinterventions (mortality 5.6%), the majority of which were minor endovascu-
lar reinterventions (mortality 3.0%).However,minor open (mortality 6.9%) and
major reinterventions (mortality 12.1 %) were also more common after EVAR
than open repair. OAR patients had more laparotomy related reinterventions
(mortality 8.1%) and readmissions without surgery (mortality 10.9%). Overall
30 daymortality after any reintervention or readmission was higher after EVAR
than OAR (9.8% vs 7.5%, p0.001).
Conclusion: Overall reintervention and readmission, and their associ-
ated 30 day mortality, are higher after EVAR with up to 6 years of follow-up
which likely contributes to loss of late survival benefit after EVAR.
Follow-up year
Annual reinterventions or readmissions per patient-year
30 day
mortality
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Overall
Endo
/open
Endo
/open
Endo
/open
Endo
/open
Endo
/open
Endo
/open
Endo
/open
All Reinterventions
or Readmissions
7.6% /
8.2%
6.2% /
6.3%
5.8% /
4.5%
4.6% /
4.3%
4.4% /
4.3%
3.1% /
2.4%
5.9% /
5.7%
8.6%
- Rupture
Readmission
0.2% /
0.1%
0.4% /
0.1%
0.5% /
0.1%
0.5% /
0.0%
0.5% /
0.1%
0.4% /
0.0%
0.4% /
0.1%
26.8%
- AAA-related
Reintervention
4.0% /
1.2%
2.8% /
0.7%
3.0% /
0.6%
2.2% /
0.8%
2.2% /
0.5%
1.6% /
0.3%
3.0% /
0.8%
5.6%
- Rupture Repair 0.0% /
0.0%
0.1% /
0.0%
0.2% /
0.0%
0.1% /
0.0%
0.2% /
0.0%
0.2% /
0.0%
0.1% /
0.0%
30.2%
- Major
Reintervention
0.5% /
0.3%
0.4% /
0.1%
0.4% /
0.1%
0.3% /
0.2%
0.3% /
0.1%
0.2% /
0.0%
0.4% /
0.1%
12.1%
- Minor
Reintervention
3.8% /
1.0%
2.5% /
0.6%
2.5% /
0.5%
1.9% /
0.7%
2.0% /
0.4%
1.4% /
0.3%
2.7% /
0.7%
4.4%
- Open 1.4% /
0.8%
0.5% /
0.4%
0.4% /
0.3%
0.5% /
0.5%
0.3% /
0.2%
0.3% /
0.2%
0.7% /
0.5%
6.9%
- Endovascular 2.4% /
0.2%
2.0% /
0.2%
2.1% /
0.2%
1.5% /
0.2%
1.6% /
0.2%
1.0% /
0.1%
2.0% /
0.2%
3.0%
- Laparotomy-
Related
Reinterventions
1.8% /
4.0%
1.3% /
3.6%
1.2% /
2.0%
1.0% /
1.8%
0.8% /
1.9%
0.4% /
1.0%
1.3% /
2.8%
8.1%
- Readmission for
Bowel
Obstruction or
Ventral Hernia
without Surgery
2.3% /
3.8%
2.3% /
2.6%
1.9% /
2.4%
1.6% /
2.4%
1.6% /
2.7%
1.0% /
1.4%
2.0% /
2.8%
10.9%
- Amputation 0.2% /
0.4%
0.2% /
0.2%
0.1% /
0.1%
0.1% /
0.1%
0.1% /
0.1%
0.1% /
0.0%
0.2% /
0.2%
7.2%
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Iliac Branched Devices: Technical Aspects and Midterm Patency
Marcelo Ferreira, Luiz Lanziotti, Marcelo Monteiro. SITE - Rio de Janeiro,
Rio de Janeiro, Brazil
Objective: This study presents technical aspects, midterm results and
complications using iliac bifurcation devices (IBD) and determine its feasi-
bility and safety in patients with aortoiliac or common iliac artery aneurysms
(CIAA), including those with bilateral disease. METHODS: Since 2006, 47
IBD were implanted in 37 patients and followed for a meanSD of 11,6
7,5 months (range 2 to 31).Treated CIAA were unilateral in 27 patients and
bilateral in 10. Two patients with bilateral CIAA did not have simultaneous
aortic aneurysm and one had an anastomotic pseudoaneurysm. Two patients
underwent combined thoracoabdominal aneurysm treatment with branched
endografts and one underwent combined juxta-renal aneurysm repair with a
fenestrated device. Eleven (23,4%) CIAA received the Helical Iliac Side
Branch device and the remaining 36 (76,6%) received the Zenith Bifurcated
Iliac Sidebranch.
Results: Technical success was 97,3% of 47 intended to treat CIAA
(migration failure in one patient). There were no deaths and no conversions
to open repair. During follow-up five (10,6%) hypogastric branch occlusions
occurred in five patients, all within the first 12 months, and one patient
developed persistent buttock claudication. Two unilateral occlusions oc-
curred in patiens with bilateral repair, sparring the contralateral CIA. No
endoleak, modular side branch disconnection or late iliac rupture were
observed. Cumulative patency was 74% up to 31 months.
Conclusions: Bilateral CIAA treatment with IBD should be consid-
ered standard treatment for bilateral disease.The use of IBD to preserve
pelvic circulation is safe and feasible for most patients CIAA, including
those with concomitant Abdominal or Thoracoabdominal Aortic Aneu-
rysms.
